These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 22071969)
21. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
22. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558 [TBL] [Abstract][Full Text] [Related]
23. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998 [TBL] [Abstract][Full Text] [Related]
24. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034 [TBL] [Abstract][Full Text] [Related]
25. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
26. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558 [TBL] [Abstract][Full Text] [Related]
27. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model. Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398 [TBL] [Abstract][Full Text] [Related]
28. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model. Saito A; Morishita N; Mitsuoka C; Kitajima S; Hamada K; Lee KM; Kawabata M; Fujisawa M; Shirakawa T J Gene Med; 2011 Jun; 13(6):353-61. PubMed ID: 21674738 [TBL] [Abstract][Full Text] [Related]
29. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Cerullo V; Koski A; Vähä-Koskela M; Hemminki A Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247 [TBL] [Abstract][Full Text] [Related]
30. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131 [TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Weber J Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057 [TBL] [Abstract][Full Text] [Related]
32. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547 [TBL] [Abstract][Full Text] [Related]
33. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354 [TBL] [Abstract][Full Text] [Related]
34. Oncolytic HSV as a vector in cancer immunotherapy. Li H; Zhang X Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972 [TBL] [Abstract][Full Text] [Related]
35. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160 [TBL] [Abstract][Full Text] [Related]
36. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
37. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A Gene Ther; 2009 Aug; 16(8):1009-20. PubMed ID: 19440223 [TBL] [Abstract][Full Text] [Related]
38. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540 [TBL] [Abstract][Full Text] [Related]
40. Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy. Choi JW; Kang E; Kwon OJ; Yun TJ; Park HK; Kim PH; Kim SW; Kim JH; Yun CO Gene Ther; 2013 Sep; 20(9):880-92. PubMed ID: 23514707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]